Abstract:Background C-reactive protein (CRP) is a candidate biomarker for major depressive disorder (MDD), but it is unclear how peripheral CRP levels relate to the heterogeneous clinical phenotypes of the disorder. Aim To explore CRP in MDD and its phenotypic associations. Method We recruited 102 treatment-resistant patients with MDD currently experiencing depression, 48 treatment-responsive patients with MDD not currently experiencing depression, 48 patients with depression who were not receiving medication and 54 healthy volunteers. High-sensitivity CRP in peripheral venous blood, body mass index (BMI) and questionnaire assessments of depression, anxiety and childhood trauma were measured. Group differences in CRP were estimated, and partial least squares (PLS) analysis explored the relationships between CRP and specific clinical phenotypes. Results Compared with healthy volunteers, BMI-corrected CRP was significantly elevated in the treatment-resistant group ( P = 0.007; Cohen's d = 0.47); but not significantly so in the treatment-responsive ( d = 0.29) and untreated ( d = 0.18) groups. PLS yielded an optimal two-factor solution that accounted for 34.7% of variation in clinical measures and for 36.0% of variation in CRP. Clinical phenotypes most strongly associated with CRP and heavily weighted on the first PLS component were vegetative depressive symptoms, BMI, state anxiety and feeling unloved as a child or wishing for a different childhood. Conclusions CRP was elevated in patients with MDD, and more so in treatment-resistant patients. Other phenotypes associated with elevated CRP included childhood adversity and specific depressive and anxious symptoms. We suggest that patients with MDD stratified for proinflammatory biomarkers, like CRP, have a distinctive clinical profile that might be responsive to second-line treatment with anti-inflammatory drugs. Declaration of interest S.R.C. consults for Cambridge Cognition and Shire; and his input in this project was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z). E.T.B. is employed half time by the University of Cambridge and half time by GlaxoSmithKline; he holds stock in GlaxoSmithKline. In the past 3 years, P.J.C. has served on an advisory board for Lundbeck. N.A.H. consults for GlaxoSmithKline. P.d.B., D.N.C.J. and W.C.D. are employees of Janssen Research & Development, LLC., of Johnson & Johnson, and hold stock in Johnson & Johnson. The other authors report no financial disclosures or potential conflicts of interest.

Treatment-resistant depression and peripheral C-reactive protein

The Association of Depressive Symptoms With Plasma C-Reactive Protein in Patients With Major Depressive Disorder Under Treatment

Disturbed sex hormones milieu in males and females with major depressive disorder and low-grade inflammation

Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation

Biological correlates of treatment resistant depression: a review of peripheral biomarkers

An inflamed subtype of difficult-to-treat depression

Monomeric C-reactive protein as a biomarker for major depressive disorder

Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis

Association between Depression and C-Reactive Protein

Network analysis of depressive symptoms and C-reactive protein levels in major depressive disorder

Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder

Associations between C-reactive protein and individual symptoms of depression in a lower-middle income country

The association between C-reactive protein, mood disorder, and cognitive function in UK Biobank

Clinical and Biological Factors Are Associated with Treatment-Resistant Depression

C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study

- Individuals with major depressive disorder and inflammation exhibited sex hormone imbalance: new insights from the Biomarker in Depression (BIODEP) study

Prediction of Delirium in Critically Ill Patients with Elevated C-reactive Protein

Increased Plasma Levels of Competing Amino Acids, Rather Than Lowered Plasma Tryptophan Levels, Are Associated with a Non-Response to Treatment in Major Depression.

Study of decreased serum levels of C1q/TNF-related protein 4 (CTRP4) in major depressive disorder

Association between C-reactive protein and mood disorder in a representative sample of the Canadian population: analysis of CHMS data 2013–2014

Changes in Insulin Resistance Following Antidepressant Treatment Mediate Response in Major Depressive Disorder.